Skytrofa Disease Interactions
There are 6 disease interactions with Skytrofa (lonapegsomatropin).
- Active malignancy
- Acute critical illness
- Prader-Willi Syndrome
- Diabetes
- Hypoadrenalism
- Hypothyroidism
Human growth hormone (applies to Skytrofa) active malignancy
Major Potential Hazard, Moderate plausibility. Applicable conditions: Lung Cancer, Bladder Cancer, Brain/Intracranial Tumor, Skin Cancer, Prostate Cancer, Breast Cancer
Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.
References
- (2004) "Product Information. Serostim (somatropin)." Serono Laboratories Inc
- (2004) "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc
- (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
- (2023) "Product Information. Ngenla (somatrogon)." Pfizer U.S. Pharmaceuticals Group
Human growth hormone (applies to Skytrofa) acute critical illness
Major Potential Hazard, Moderate plausibility. Applicable conditions: Acute (Surgical) Abdomen, Pulmonary Impairment, Sepsis
Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.
References
- (2004) "Product Information. Serostim (somatropin)." Serono Laboratories Inc
- (2004) "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc
- (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
- (2023) "Product Information. Ngenla (somatrogon)." Pfizer U.S. Pharmaceuticals Group
Human growth hormone (applies to Skytrofa) Prader-Willi Syndrome
Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment, Sleep Apnea, Obesity
Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.
References
- (2004) "Product Information. Serostim (somatropin)." Serono Laboratories Inc
- (2004) "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc
- (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
- (2023) "Product Information. Ngenla (somatrogon)." Pfizer U.S. Pharmaceuticals Group
Growth hormone (applies to Skytrofa) diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
The use of growth hormone has been associated with resistance to insulin. Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy. The dose of antihyperglycemic drugs (insulin or oral/injectable agents) may require adjustment.
References
- (2001) "Product Information. Nutropin (somatropin)." Genentech
- (2001) "Product Information. Protropin (somatrem)." Genentech
- (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
Growth hormone (applies to Skytrofa) hypoadrenalism
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency
Patients with or at risk for pituitary hormone deficiency(s) may experience reduced serum cortisol and/or unmasking of central (secondary) hypoadrenalism. Glucocorticoid replacement may require increased maintenance or stress doses. Monitor for reduced serum cortisol and/or the need for glucocorticoid dose increases.
References
- (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
Growth hormone (applies to Skytrofa) hypothyroidism
Moderate Potential Hazard, Moderate plausibility.
The use of growth hormone has been associated with the development of hypothyroidism. Patients should be monitored baseline and periodically for adequate thyroid function. Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone.
References
- (2001) "Product Information. Nutropin (somatropin)." Genentech
- (2001) "Product Information. Protropin (somatrem)." Genentech
- (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.
Skytrofa drug interactions
There are 433 drug interactions with Skytrofa (lonapegsomatropin).
Skytrofa alcohol/food interactions
There is 1 alcohol/food interaction with Skytrofa (lonapegsomatropin).
More about Skytrofa (lonapegsomatropin)
- Skytrofa consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: growth hormones
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.